ArticleFamilial cancer2022
Adaptation and early implementation of the PREdiction model for gene mutations (PREMM
Article in Familial cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- ORCA, a values-based decision aid for selecting additional findings from genomic sequencing in adults: Efficacy results from a randomized trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Trial
- Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome.JCO precision oncology · 2025Article
- Usability, Engagement, and Report Usefulness of Chatbot-Based Family Health History Data Collection: Mixed Methods Analysis.Journal of medical Internet research · 2024Article
- Hereditary Cancer Genetic Testing: 30 Years of Impact on Cancer Care.Delaware journal of public health · 2024Article
- Improving Care for Marginalized Populations at Risk for Hereditary Cancer Syndromes: Innovations that Expanded Reach in the CHARM Study.Public health genomics · 2024Article
- Feasibility of an electronic patient-facing cancer family history tool in medically underserved populations.Genetics in medicine open · 2024Article
- Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study.Cancer medicine · 2023Article
- Medical interpreter-mediated genetic counseling for Spanish preferring adults at risk for a hereditary cancer syndrome.Journal of genetic counseling · 2023Article
- Evaluating cancer genetic services in a safety net system: overcoming barriers for a lasting impact beyond the CHARM research project.Journal of community genetics · 2023Article
- Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews.Hereditary cancer in clinical practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
Abstract
Lynch syndrome (LS) is the most common inherited cause of colorectal and endometrial cancers. Identifying individuals at risk for LS without personal cancer history requires detailed collection and assessment of family health history. However, barriers exist to family health history collection, especially in historically underserved populations. To improve LS risk assessment in historically underserved populations, we adapted the provider-facing PREdiction Model for gene Mutations (PREMM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.